TITLE

Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: A double blind and randomized trial [ISRCTN64132371]

AUTHOR(S)
Akhondzadeh, Shahin; Mohammadi, Mohammad-Reza; Khademi, Mojgan
PUB. DATE
January 2004
SOURCE
BMC Psychiatry;2004, Vol. 4, p9
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Attention-deficit hyperactivity disorder is an early-onset, clinically heterogenous disorder of inattention, hyperactivity, and impulsiveness. The diagnosis and treatment of attention-deficit hyperactivity disorder continues to raise controversy, and, there is also an increase in treatment options. In this 6-week double blind, placebo controlled-trial, we assessed the effects of zinc plus methylphenidate in the treatment of children with attention deficit hyperactivity disorder. To the best of our knowledge, this study is the first double blind and placebo controlled clinical trial assessing the adjunctive role of zinc in ADHD. Methods: Our subjects were 44 outpatient children (26 boys and 18 girls) between the ages of 5-11 (mean ± SD was 7.88 ± 1.67) who clearly met the DSM IV diagnostic criteria for attention-deficit hyperactivity disorder and they were randomized to methylphenidate 1 mg/kg/day + zinc sulfate 55 mg/ day (with approximately 15 mg zinc element) (group 1) and methylphenidate 1 mg/kg/day + placebo (sucrose 55 mg) (group 2) for a 6 week double blind clinical trial. The principal measure of the outcome was the Teacher and Parent ADHD Rating Scale. Patients were assessed by a child psychiatrist at baseline, 14, 28 and 42 days after the medication started. Results: The present study shows the Parent and Teacher Rating Scale scores improved with zinc sulfate over this 6-week, double blind and placebo controlled trial. The behavior of the two treatments was not homogeneous across the time. The difference between the two protocols was significant as indicated by the effect on the group, the between-subjects factor (F = 4.15, d.f. = 1, P = 0.04; F = 4.50, d.f. = 1, P = 0.04 respectively). The difference between the two groups in the frequency of side effects was not significant. Conclusions: This double-blind, placebo-controlled study demonstrated that zinc as a supplementary medication might be beneficial in the treatment of children with attention-deficit hyperactivity disorder. However, further investigations and different doses of zinc are required to replicate these findings in children with ADHD.
ACCESSION #
29323650

 

Related Articles

  • Behavior Drugs & Children: An Overview. Bailey, Ellen; Carson-Dewitt, Rosalyn // Points of View: Behavior Drugs & Children;9/30/2019, p1 

    The article presents an overview of the use of behavior drugs in treating children with behavior problems in the U.S. It is noted that based on statistics, suicide due to depression is the third leading cause of death among people aged 15 to 24 in spite of the use of antidepressants and...

  • A Dose-Ranging Study of Behavioral and Pharmacological Treatment in Social Settings for Children with ADHD. Pelham, William; Burrows-MacLean, Lisa; Gnagy, Elizabeth; Fabiano, Gregory; Coles, Erika; Wymbs, Brian; Chacko, Anil; Walker, Kathryn; Wymbs, Frances; Garefino, Allison; Hoffman, Martin; Waxmonsky, James; Waschbusch, Daniel // Journal of Abnormal Child Psychology;Aug2014, Vol. 42 Issue 6, p1019 

    Placebo and three doses of methylphenidate (MPH) were crossed with 3 levels of behavioral modification (no behavioral modification, NBM; low-intensity behavioral modification, LBM; and high-intensity behavior modification, HBM) in the context of a summer treatment program (STP). Participants...

  • Positive Effects of Methylphenidate on Social Communication and Self-Regulation in Children with Pervasive Developmental Disorders and Hyperactivity. Jahromi, Laudan; Kasari, Connie; McCracken, James; Lee, Lisa; Aman, Michael; McDougle, Christopher; Scahill, Lawrence; Tierney, Elaine; Eugene Arnold, L.; Vitiello, Benedetto; Ritz, Louise; Witwer, Andrea; Kustan, Erin; Ghuman, Jaswinder; Posey, David // Journal of Autism & Developmental Disorders;Mar2009, Vol. 39 Issue 3, p395 

    This report examined the effect of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity in a secondary analysis of RUPP Autism Network data. Participants were 33 children (29 boys) between the ages of 5 and 13 years who...

  • Suicidality risk associated with atomoxetine.  // WHO Drug Information;2006, Vol. 20 Issue 1, p9 

    The article reports on the approval of a norepinephrine re-uptake inhibitor atomoxetine, for the treatment of attention deficit hyperactivity disorder in children 6 years of age and older, in adolescents and adults. According to the manufacturer of the drug, there is an increased risk of...

  • Finding Guidance Amid Uncertainty of ADHD Diagnosis. Shakil, Amer // American Family Physician;5/1/2001, Vol. 63 Issue 9, p1694 

    Editorial. Focuses on issues related to the management of attention-deficit hyperactivity disorder (ADHD) among children. Establishment of criteria for ADHD; Recommendations for the management of ADHD; Importance of screening the school performance of children.

  • Attention disorder in children: is the literature purged? Was it ever tainted? Knoll, Elizabeth; Shaywitz, Sally E.; Knoll, E // JAMA: Journal of the American Medical Association;4/28/89, Vol. 261 Issue 16, p2330 

    Comments on an article on medication overuse in the treatment of attention deficit hyperactivity disorder, previously published in the October 21, 1988, issue of the 'Journal of the American Medical Association.' Review of relevant literature; Fraud in research on the treatment of the disorder.

  • FDA Preliminary Report: Safety of Stimulant Medications. Stein, Martin T. // Archives of Disease in Childhood;Jul2006, Vol. 91 Issue 7, p619 

    The article reports that a U.S. Food and Drug Administration committee has voted to recommend that stimulant medications prescribed for attention deficit hyperactivity disorder (ADHD) carry a strong "black box" warning about potential cardiovascular risks. Pediatricians who prescribe medications...

  • Hiding parts of one's self from others - a grounded theory study on teenagers diagnosed with ADHD. Hallberg, Ulrika; Klingberg, Gunilla; Setsaa, Wenche; Moller, Anders // Scandinavian Journal of Disability Research;Sep2010, Vol. 12 Issue 3, p211 

    The aim of this study was to gain deeper knowledge of how teenagers with the diagnosis of ADHD experience their disorder, treatment and the consequences of diagnosis and treatment in their daily lives. Ten teenagers were interviewed in depth. The interviews were analyzed according to the...

  • Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: Preliminary indications from a secondary analysis of the COMACS study data. Sonuga-Barke, Edmund J. S.; Swanson, James M.; Coghill, David; DeCory, Heleen H.; Hatch, Simon J. // BMC Psychiatry;2004, Vol. 4, p28 

    Background: Methylphenidate (MPH) is commonly prescribed in the treatment of Attention-Deficit/ Hyperactivity Disorder or ADHD. Concerta and Metadate CD are once-daily formulations of MPH using different delivery mechanisms resulting in different pharmacokinetic profiles. A recent study (COMACS)...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics